Dr Parul Ganju chose to forgo a US research opportunity to focus on developing a treatment for vitiligo after witnessing its profound impact on patients. In 2016, she co-founded Ahammune Biosciences, where the lead drug candidate, AB1001, targets the disease’s underlying immune pathway rather than broadly suppressing immunity. Now in Phase 2 clinical trials, the […]
阅读更多
